09:31 uur 26-05-2016

Amulet Capital Partners, LP verwerft SynteractHCR

GREENWICH, Conn.–(BUSINESS WIRE)– Amulet Capital Partners, LP (Amulet), een private-equity-investeerder uit het middensegment met exclusieve focus op de gezondheidszorg, heeft vandaag bekendgemaakt dat het SynteractHCR Holdings Corporation heeft aangekocht. SynteractHCR is een toonaangevende organisatie voor uitbesteed klinisch onderzoek in de fases I tot en met IV. Het bedrijf voert deze onderzoeken uit voor opkomende tot middelgrote biofarmaceutische cliënten uit de Verenigde Staten, Europa en Azië. Voorwaarden voor de transactie zijn niet openbaar gemaakt.

SynteractHCR, met hoofdzetel in San Diego, is in 1995 opgericht en staat in de mondiale top 20 van aanbieders van uitbesteed onderzoek. Het bedrijf heeft meer dan achthonderd personeelsleden in 21 landen. SynteractHCR heeft een reputatie van klinische uitmuntendheid in complexe onderzoeken binnen uiteenlopende therapeutische velden. Daardoor heeft het bedrijf sinds zijn oprichting bijgedragen aan meer dan 230 goedkeuringen van producten. SynteractHCR heeft meer dan 3500 projecten geleid waaraan in totaal meer dan 700 duizend patiënten uit circa zestig landen deelnamen.



Amulet Capital Partners, LP Announces Acquisition of SynteractHCR


GREENWICH, Conn.–(BUSINESS WIRE)– Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm based in Greenwich, CT focused exclusively on the healthcare sector, announced today that is has acquired SynteractHCR Holdings Corporation (“SynteractHCR”), a leading contract research organization (CRO) focused on Phase I‐IV clinical trials for emerging to mid-sized biopharma clients in the U.S., Europe and Asia. Terms of the transaction were not disclosed.

Headquartered outside San Diego, California, SynteractHCR was founded in 1995 and is now a top 20 global full‐service CRO. The company has over 800 staff members across 21 countries. SynteractHCR has a reputation for clinical excellence in complex trials in a broad range of therapeutic areas, contributing to more than 230 product approvals since its founding. The company has run over 3,500 projects including more than 700,000 patients in 60+ countries.

This is the first acquisition by Amulet, founded in 2015 by Ramsey Frank and Jay Rose. The partners and principals of Amulet’s investment team have approximately 40 years of private equity experience and bring together a unique blend of leveraged buyout, growth capital, and restructuring skills, supplemented by significant expertise across a wide range of healthcare verticals, including the CRO sector.

SynteractHCR CEO Wendel Barr said, “We welcome this new relationship with Amulet Capital Partners as they understand our positioning and the opportunities available to us. New funding will allow us to enhance our full service capabilities, hire even more international clinical development experts to support global trials, and increase our ability to help our clients successfully navigate the complex drug development process.”

Ramsey Frank, Partner and Co-founder of Amulet said, “The importance of CROs to the pharmaceutical and biotech industries has grown significantly in the last decade, and the current market dynamic is very favorable for middle market CROs, particularly those focused on small and mid-sized biopharma clients. SynteractHCR is a leading CRO with global scale and solid earnings momentum, well positioned to take advantage of the strong long-term growth prospects in the sector. We are excited to partner with Wendel Barr and his experienced management team to continue to expand SynteractHCR’s business.”

Frank added, “As a firm, Amulet is differentiated through our ability to bring extensive financial resources and healthcare experience, especially in the CRO sector. We will work closely with management to build on SynteractHCR’s leading market position and enhance the long-term prospects for the company. SynteractHCR will serve as a platform in the industry as we seek to invest in or acquire complementary businesses that will expand the company’s geographic footprint and areas of therapeutic expertise.”

SynteractHCR’s prior owner, Gryphon Investors, a middle-market private equity firm based in San Francisco, CA, acquired a majority interest in SynteractHCR in 2008 and supported the company’s growth into a global business.

Capital One, N.A. and certain private debt funds managed by THL Credit Advisors LLC provided debt financing for the transaction. Wells Fargo Securities acted as exclusive financial advisor to SynteractHCR.

About SynteractHCR

SynteractHCR is a full-service international contract research organization (CRO) with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “ Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.

About Amulet Capital Partners, LP

Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. Amulet Capital Partners’ investment team has approximately 40 years of private equity experience. For additional information, please visit www.amuletcapital.com.


Contact for SynteractHCR:
Beth Walsh, 760-230-2424
Contact for Amulet Capital Partners:
Melissa Sheer, 917-690-2199

Check out our twitter: @NewsNovumpr